Dec. 2 at 10:06 PM
$CHRS Certainly a lot of different opinions on CHRS. I see a company on track to get to break even in mid 2028, with cash runway to the end of 2026 and Udenyeca earnouts that will extend the runway to mid-2027 if achieved. They will need about 150M to tie them over to the finish line. They have repeatedly said they intend to sell the rights to one or more of the drugs (outside the U.S.) to get there. We can reasonably expect this to happen IF trial results are good, validating the pipeline. In the interim, we will have doom and gloom and periods of happy hysteria based on whether the stock is trading closer to 1 or 2. As long as it does not reverse split, I am waiting and expect us to stay in that range. With a cost basis in the middle, sure, I feel shitty some days and pretty good on others ... but my sights are set on the company unlocking the value, which is at least
$500M market cap in my opinion.
